The Safety and Efficacy of New Drug Approval.¶
Gieringer, D. H. (1985). The Safety and Efficacy of New Drug Approval. Cato Journal, 5(1), 177-201.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Omission Bias
- In policy and regulation it is the asymmetric scrutiny of errors of commission (a drug approved that causes harm) over errors of omission (a beneficial drug delayed or denied, whose victims are statistical and unattributed), biasing regulators toward inaction.
This sourceDocuments the FDA's asymmetric incentive to avoid errors of commission (approving a harmful drug, with visible victims) over errors of omission (delaying or denying a beneficial drug, whose victims are statistical and unattributed), biasing the agency toward inaction.
- In policy and regulation it is the asymmetric scrutiny of errors of commission (a drug approved that causes harm) over errors of omission (a beneficial drug delayed or denied, whose victims are statistical and unattributed), biasing regulators toward inaction.
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:5f3b2ee3a213 · see in the full table